Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients

Table 1

Selection criteria and patients inclusion.

Selection criteria	Number of patients excluded	Number of patients remained			Total
		SIM 2002	EAE 2003–2005	SIM 2006
First pancreas transplant		106	189	61	356
Alemtuzumab for conversion	4	102	189	61	352
Alemtuzumab for rejection treatment in the first year after transplant	3	99	189	61	349
Alemtuzumab for induction	1	99	189	60	348
ATG for induction	8	99	181	60	340
Methylprednisone for induction	1	99	180	60	339
Daclizumab for induction	1	99	179	60	338
Study group		SIM	EAE		Total
		159	179		338

Conversion therapy was defined as the need to substitute alemtuzumab for calcineurin inhibitor(s) due to calcineurin inhibitor-associated nephropathy. ATG, antithymocyte globulin; EAE: extended alemtuzumab exposure; SIM: standard induction and maintenance.